DENODO
23.6.2022 09:03:13 CEST | Business Wire | Press release
Denodo , the leader in data management, today announced that its customer LeasePlan, headquartered in the Netherlands and with business operations across the globe, has been chosen as the winner of the IDC’s 2022 European Data Strategy & Innovation Awards in the Data Management Excellence category. The winners were announced on June 9th, 2022 at the special awards ceremony as part of IDC’s 2022 European Data and Intelligence Summit in Sintra, Portugal.
IDC's European Data Strategy & Innovation Awards are focused on celebrating the European organizations that are blazing trails in this area and on improving awareness of "what works". According to Neil Ward-Dutton, VP AI, Automation and Analytics Europe, at IDC, "This is the third year of our European Data Strategy and Innovation Awards, and we were delighted to receive so many high-quality nominations from across the region."
IDC received 34 nominations for 3 award categories and LeasePlan edged past the other nominees in the Data Management excellence category to win the coveted title. According to IDC, "Nominations in this category were from enterprises that could demonstrate significant advances in their ability to manage data effectively and efficiently at scale. The overall winner was LeasePlan, for its creation of a logical data fabric across all its key data sources, which has helped the company in creating transformational new use cases in customer experience and convenience, such as predictive vehicle maintenance programs."
LeasePlan, one of the world’s leading Car-as-a-Service companies, has approximately 1.9 million vehicles under management in 29 countries. These vehicles generate a large amount of data that has to be integrated and contextualized to support the customer journey. What followed was LeasePlan’s next-gen data strategy, envisioned to encompass a logical data fabric across all its key data sources – modern, cloud-based and legacy – with a single point of access, to be supported by a Global Data Hub. According to Sumit Arya, the Head of Data and Solution Architecture at LeasePlan, “The Logical Data Fabric built on the Denodo Platform is a critical component of LeasePlan’s Global Data Hub to seamlessly build a foundation for data self-service and simplify transparent data migration. It has enabled us to create new business services and best support our drivers on every step of their journey.” Denodo Platform has also supported the data governance needs of the organization and facilitated its cloud modernization efforts with zero downtime for BI reporting while migrating legacy data marts to the Cloud in various business units across geographies.
“We want to congratulate our customer LeasePlan for its efforts and the innovative use of the Denodo Platform to support its data management needs and key business initiatives,” said Ravi Shankar, Senior Vice President and Chief Marketing Officer at Denodo. “The Denodo Platform provides an abstraction layer to create a single, secure point-of-entry to LeasePlan's entire data ecosystem. LeasePlan has also built a centralized framework for data governance by leveraging the metadata management and data catalog capabilities of the Denodo platform to ensure the highest level of self-service and data security. We are thrilled to see LeasePlan credited for the way they have applied our platform to make such an impact.”
Please Tweet : https://ctt.ac/hUnsp
About LeasePlan
LeasePlan, one of the world’s leading Car-as-a-Service companies, is transforming from an analogue to a fully digital business model. LeasePlan worked with Denodo and other technologies to create a logical data fabric across all its key data sources – modern, cloud-based and legacy – with a single point of access. This gives a foundation for data self-service and simplifies transparent data migration to the Cloud. Most notably, the data fabric approach has helped the company in creating transformational new use cases in customer experience and convenience, such as predictive vehicle maintenance programs.
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading data integration, management, and delivery platform using a logical approach to enable self-service BI, data science, hybrid/multi-cloud data integration, and enterprise data services. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across large enterprises and mid-market companies in 30+ industries have received payback in less than 6 months. For more information, visit www.denodo.com or call +1 877 556 2531 (US) / +44 (0) 20 7869 8053 (UK) / +65 6950 7489 (Singapore).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005168/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom